Paid Clinical Trials Richardson
Discover 1,841 paid clinical trials in Richardson, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Magnetic Resonance Imaging
Photon Beam Radiation Therapy
Questionnaire Administration
Temozolomide
Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT05552976
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Mezigdomide
Carfilzomib
Dexamethasone
CenerimodA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Sponsor:
Idorsia Pharmaceuticals Ltd.
Location:
Code:
NCT05672576
Conditions
Lupus Erythematosus, Systemic
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Cenerimod
Placebo
AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Sponsor:
AbbVie
Location:
Code:
NCT05711394
Conditions
Episodic Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Atogepant
Placebo-Matching Atogepant
DexamethasonePerivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
Sponsor:
Mercator MedSystems, Inc.
Location:
Code:
NCT04858776
Conditions
Iliofemoral; Thrombosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Perivascular dexamethasone
Perivascular sham
Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor:
Allogene Therapeutics
Location:
Code:
NCT06500273
Conditions
Large B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemacabtagene ansegedleucel
ALLO-647
Fludarabine
Cyclophosphamide
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
AP-CD/LDA Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
Sponsor:
Intec Pharma Ltd.
Location:
Code:
NCT02615873
Conditions
Parkinson's Disease
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Accordion Pill™ Carbidopa/Levodopa
PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
Olaparib
MK-4280
RavulizumabStudy of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
XL092 & NivolumabStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Sponsor:
Exelixis
Location:
Code:
NCT05678673
Conditions
Non-Clear Cell Renal Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
XL092
Nivolumab
Sunitinib Malate